Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFORM levofloxacin pharmacokinetics study in children exposed to MDR-TB
PACTR202008476090763Phase 1Completed
- Sponsor
- Tygerberg Hospital
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of levofloxacin in multidrug-resistant tuberculosis (MDR-TB) (2 arms), sponsored by Tygerberg Hospital. Primary endpoint: Relative bioavailability of levofloxacin formulations. Started Sep 2020; status: completed.
02
Drugs
levofloxacin
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on PACTR202008476090763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202008476090763.